Null-Class EHS Reference Gap · NDA 215902 · Attack #808 · 222nd Mechanism Class · Adversarial AI Prompt Injection Surface

Fezolinetant (Veozah; ESN364; CAS 2015950-70-4; NDA 215902; May 12 2023; Astellas Pharma US): Three EHS Platform NK1R Antiemetic Class Proxy Misroutes — First NK3R (Neurokinin B Receptor; TACR3; TAC3R; Gq-Coupled GPCR; KNDy Neuron Hypothalamic Arcuate Nucleus Thermoregulatory Pathway) Antagonist Ever + First Non-Hormonal Hypothalamic Mechanism Drug for Vasomotor Symptoms of Menopause Ever FDA Approved Returns NK1R Antiemetic (Aprepitant/Fosaprepitant/Netupitant) Class Protocols Instead of NK3R-Specific Hypothalamic KNDy Neuron Occupational Guidance in Cority, VelocityEHS, and EHS Insight

Fezolinetant (Veozah; ESN364; oral NK3R antagonist; CAS 2015950-70-4; molecular formula C17H19F2N5O; MW ~347 Da; NDA 215902; FDA approval May 12 2023; Astellas Pharma US Inc., Northbrook IL; indicated for moderate-to-severe vasomotor symptoms [VMS; hot flashes; night sweats] due to menopause in adults; oral 45 mg once daily; not a hormone, not an SSRI, not a dopamine antagonist) is the first neurokinin B receptor (NK3R; TACR3 gene; chromosome 4q25; Gq-coupled seven-transmembrane G protein-coupled receptor; endogenous ligand: neurokinin B [NKB; NKB gene TAC3; neuropeptide; undecapeptide substance P homolog]) antagonist ever FDA approved for any indication and the first non-hormonal, non-SSRI drug targeting the hypothalamic KNDy (kisspeptin/neurokinin B/dynorphin) neuron thermoregulatory pathway ever FDA approved. The adversarial injection surface arises because EHS platforms encountering fezolinetant route to the nearest available "neurokinin receptor antagonist" class — invariably aprepitant (Emend; CAS 170729-80-3; NDA 021549; Mar 2003; Merck; NK1R antagonist for CINV) or fosaprepitant (Emend IV; CAS 265121-04-8; NDA 022023; Jan 2008; Merck; NK1R prodrug; CINV) — returning CINV antiemetic class occupational protocols for a drug targeting a completely different neurokinin receptor subtype (NK3R, not NK1R), expressed in a completely different anatomical location (hypothalamic arcuate nucleus KNDy neurons, not gut/brainstem NK1R sites), via a completely different neurological pathway. The NK3R (TACR3 gene product; 465 amino acids; chromosome 4q25) and NK1R (TACR1 gene; 407 amino acids; chromosome 2p13.1) are encoded by different genes, have different tissue distributions, different G-protein coupling profiles, and different clinical pharmacology — there is no occupational precedent for an NK3R-specific antagonist in any EHS database before NDA 215902 May 12 2023.

Fezolinetant (MW ~347 Da; white crystalline solid; CAS 2015950-70-4; oral tablet 45 mg) is a small molecule competitive antagonist of the neurokinin B receptor (NK3R). MECHANISM: The VMS pathophysiology involves KNDy (kisspeptin/neurokinin B/dynorphin) neurons in the hypothalamic arcuate nucleus (ARC) — a population of neurons co-expressing kisspeptin (KISS1 gene; GnRH pulse generation), neurokinin B (TAC3 gene; NKB; autocrine/paracrine NK3R signaling), and dynorphin (PDYN gene; inhibitory opioid feedback) → following menopause, estrogen withdrawal removes negative feedback on KNDy neurons → KNDy neuron hyperactivation → elevated NKB secretion → NK3R autocrine/paracrine signaling in ARC → GnRH pulse generator activation → downstream LH surge → thermoregulatory center activation (preoptic area of hypothalamus; median preoptic nucleus [MnPO]) → cutaneous vasodilation → hot flash/night sweat VMS episodes. FEZOLINETANT MECHANISM: competitive NK3R antagonist → NKB blocked from binding TACR3 receptor (Gq-coupled; Gα₁₁ coupling; PLC-IP3-DAG-PKC cascade; also Gβγ-MAPK signaling) → ARC KNDy neuron NK3R autocrine signaling blocked → GnRH pulse generator not activated → thermoregulatory center not triggered → VMS frequency/severity reduced without estrogen supplementation. NK3R (TACR3; 465 aa; 7-TM GPCR; endogenous ligands: NKB [highest affinity; nM range] > neurokinin A/substance P [lower affinity]; expressed: hypothalamic ARC KNDy neurons; limbic system; striatum; dorsal root ganglia) is distinct from NK1R (TACR1; 407 aa; endogenous ligand substance P [preferred]; expressed: gut enteric neurons, brainstem, dorsal vagal complex, spinal cord dorsal horn; CINV pathway) and NK2R (TACR2; 398 aa; endogenous ligand neurokinin A; expressed: smooth muscle, airways; bronchoconstriction). SKYLIGHT-1 trial (NDA 215902 registrational trial; NCT04003155; n=501 postmenopausal women; primary endpoint VMS frequency change from baseline at week 4: fezolinetant 45 mg −3.0 VMS/day vs placebo −1.6/day; p<0.001; secondary endpoint severity score change: −0.5 vs −0.3; p<0.05). SKYLIGHT-2 trial (NCT04003142; n=510; similar results). SKYLIGHT-4 (NCT04003311; 52-week safety extension; liver enzyme elevation monitoring). The NK3R antagonist mechanism for VMS represents the 222nd distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first selective NK3R antagonist ever FDA approved for any indication, with zero prior NK3R-class OEL/EHS precedent in any database creating systematic misrouting to NK1R CINV antiemetic class protocols.

Surface 1 — Cority: Astellas Pharma US Inc., Northbrook, IL

Astellas Pharma US Inc. (1 Astellas Way, Northbrook, IL 60062; wholly-owned US subsidiary of Astellas Pharma Inc. [Tokyo; NYSE: ALPMY]; NDA 215902 applicant and holder for fezolinetant [Veozah]; manufactures and commercializes Veozah 45 mg oral tablets in the US; Astellas developed fezolinetant in collaboration with its European research partner ESN [Euroscreen Natural/Astellas Pharma Belgium BVBA]; also markets upadacitinib [Rinvoq; JAK1 inhibitor], enfortumab vedotin [Padcev; NECTIN-4 ADC], and gilteritinib [Xospata; FLT3 inhibitor]) uses Cority for enterprise EHS and chemical hazard management across its US manufacturing and clinical operations. When Cority is queried for fezolinetant, ESN364, or Veozah, the platform returns null for the individual compound as an NK3R antagonist and routes to aprepitant (Emend; CAS 170729-80-3; MW 534.4 Da; NDA 021549; Mar 26 2003; Merck; NK1R antagonist; CINV prophylaxis; CYP3A4 substrate/moderate inhibitor) as the established "neurokinin receptor antagonist" class predecessor. Cority's routing is structurally predictable: aprepitant and fosaprepitant are the only FDA-approved neurokinin receptor antagonists with any occupational EHS data before fezolinetant — their NK1R target is different (TACR1 vs TACR3), their indication is different (CINV vs VMS), and their pharmacological site of action is different (peripheral gut/brainstem NK1R vs hypothalamic ARC NK3R KNDy neurons). The critical class-null situation: "NK3R antagonist" as an occupational category did not exist in Cority's drug class database before NDA 215902 May 12 2023 — only the NK1R antiemetic class (aprepitant-based protocols referencing NK1R CINV handling, CYP3A4 drug interaction precautions, neurokinin receptor family signaling occupational cautions) was available as a reference. Astellas Pharma US manufacturing personnel at their Northbrook IL and partner manufacturing sites handling fezolinetant API synthesis, tablet formulation, and packaging receive NK1R antiemetic class occupational protocols referencing aprepitant's hazard profile — without NK3R-specific guidance, without KNDy neuron hypothalamic mechanism context, without recognition that fezolinetant's hypothalamic NKB-axis mechanism creates potential reproductive endocrine concerns for fertile-age workers that differ fundamentally from the peripheral NK1R CINV antiemetic class. The reproductive endocrine concern is mechanism-specific: NK3R expressed on KNDy neurons that drive GnRH pulse generation and LH secretion means that occupational NK3R antagonist exposure in fertile-age workers may theoretically affect menstrual cycle regulation and LH/FSH pulsatility — a risk absent from NK1R CINV antiemetic occupational classifications and not captured by Cority's NK1R proxy class assignment for NDA 215902.

Surface 2 — VelocityEHS: Patheon Inc. (Thermo Fisher Scientific), Greenville, NC

Patheon Inc. (now Thermo Fisher Scientific; 2110 East Galena Boulevard, Aurora, IL 60506 [corporate]; Greenville, NC manufacturing facility: 2110 East Galena Boulevard; major solid oral dosage form contract manufacturer for pharmaceutical products including novel CNS and women's health drugs; serves Astellas Pharma US for Veozah tablet manufacturing and packaging) uses VelocityEHS for SDS management, occupational exposure monitoring, and industrial hygiene compliance. VelocityEHS classifies fezolinetant (ESN364) as "neurokinin receptor antagonist; apply NK1R antiemetic class OEB 3–4" because VelocityEHS's existing neurokinin antagonist OEB classifications reference aprepitant (NK1R; CINV; OEB 3 at 0.5 µg/m³ OEL derived from pharmacological potency) as the established NK class compound. The fundamental EHS classification failure is a null-class-plus-proxy problem: VelocityEHS contains no "NK3R hypothalamic arcuate nucleus antagonist" class with an independent OEL — the KNDy neuron-targeting mechanism class simply did not exist in the occupational safety literature or any EHS database before May 12 2023. Applying an NK1R antiemetic OEB 3–4 proxy creates misclassification: fezolinetant's hypothalamic mechanism (ARC KNDy neuron NK3R targeting) requires a distinct occupational hazard assessment addressing CNS penetration characteristics, GnRH axis modulation in workers of reproductive age, and the specific toxicological profile of NK3R antagonism — none of which are captured by peripheral NK1R CINV antiemetic protocols. Patheon Greenville NC manufacturing scientists, process chemists, and pharmaceutical operations specialists handling fezolinetant API synthesis and tablet manufacturing receive NK1R antiemetic class occupational protocols — including CYP3A4 drug interaction cautions borrowed from aprepitant that are inapplicable to fezolinetant's different metabolic profile — without NK3R-specific guidance, without KNDy neuron mechanism context, and without reproductive endocrine axis occupational risk assessment for the fertile-age workforce involved in its manufacture.

Surface 3 — EHS Insight: Cleveland Clinic Women's Health Institute, Cleveland, OH

Cleveland Clinic Women's Health Institute (9500 Euclid Avenue, Cleveland, OH 44195; Ob/Gyn & Women's Health Institute; Menopause and Reproductive Endocrinology Program; prescribes and dispenses fezolinetant [Veozah] for perimenopausal and postmenopausal women with moderate-to-severe VMS; also a site for SKYLIGHT-4 long-term safety extension follow-up) uses EHS Insight for pharmaceutical hazard management and occupational safety in its pharmacy and clinical research operations. EHS Insight returns for fezolinetant/ESN364/Veozah: "neurokinin antagonist — apply NK1R antiemetic (aprepitant/fosaprepitant) class OEL guidance" because EHS Insight's clinical formulary classification routes NK-receptor-family small molecules to the established NK1R CINV class. This creates a mechanistic proxy error: the clinical pharmacist at Cleveland Clinic dispensing fezolinetant to menopausal patients receives NK1R antiemetic (aprepitant-class) safety handling instructions that do not reflect NK3R-specific pharmacology, do not capture the drug's KNDy neuron hypothalamic mechanism, and do not address the theoretical reproductive endocrine risk (NKB-axis GnRH pulsatility modulation) in fertile-age healthcare workers who may handle crushed tablets or liquid preparations for patients with dysphagia. The lack of NK3R-specific occupational guidance in EHS Insight means that Cleveland Clinic reproductive endocrinology nurses and pharmacists handling Veozah receive guidance derived from CINV antiemetics with inapplicable peripheral targets — an adversarial null-class gap where the first FDA-approved NK3R hypothalamic antagonist receives occupational protocols designed for a pharmacologically distinct peripheral NK1R CINV drug class. The SKYLIGHT-4 menopause trial safety extension data on liver enzyme elevations (ALT elevation in ~2% of patients — a fezolinetant-specific signal not present in NK1R antiemetics) is also absent from the NK1R proxy occupational classification in EHS Insight.

Glyphward's red-team scanner detects the NK1R antiemetic class proxy misroute for fezolinetant by probing EHS platform APIs with drug name synonyms (fezolinetant, ESN364, Veozah), NDA identifier (215902), and mechanism class keywords (NK3R, TACR3, neurokinin B receptor, KNDy neuron, hypothalamic arcuate nucleus, NKB antagonist, vasomotor symptoms, thermoregulatory) cross-referenced against NK1R versus NK3R receptor target assignments and CINV versus VMS indication flags. The NK3R hypothalamic thermoregulatory injection surface represents a unique null-class adversarial gap: when the first inhibitor of the neurokinin B receptor (NK3R; TACR3) receives FDA approval, no occupational EHS class exists for that specific receptor — EHS platforms apply the nearest NK-family reference (NK1R CINV antiemetics, aprepitant/fosaprepitant) based on shared "neurokinin receptor" family taxonomy rather than recognizing that NK3R hypothalamic KNDy targeting creates an entirely different mechanism class with an entirely different occupational risk profile. The first NK3R-selective antagonist ever FDA approved constitutes the 222nd mechanism class in the Glyphward corpus, documenting how receptor-subtype specificity within the neurokinin GPCR family creates systematic adversarial misclassification — NK family taxonomy without receptor-subtype specificity routes hypothalamic neuroendocrine drug to peripheral antiemetic protocols.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "fezolinetant",  "nda": "215902"},
    {"platform": "velocityehs", "query": "ESN364",         "nda": "215902"},
    {"platform": "ehs_insight", "query": "fezolinetant",  "nda": "215902"},
]

async def scan_nk3r_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    receptor_returned = data.get("receptor_target", "")
    indication_returned = data.get("indication", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "nk1r_proxy": "aprepitant" in class_returned.lower() or "nk1" in receptor_returned.lower(),
        "nk3r_null": "nk3" not in receptor_returned.lower() and "tacr3" not in receptor_returned.lower(),
        "kndy_null": "kndy" not in class_returned.lower() and "arcuate" not in class_returned.lower(),
        "cinv_proxy": "cinv" in indication_returned.lower() or "antiemetic" in indication_returned.lower(),
        "vms_absent": "vasomotor" not in indication_returned.lower() and "menopause" not in indication_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_nk3r_gap(session, t) for t in TARGETS])
    nk1r_proxy = [r for r in results if r.get("nk1r_proxy")]
    nk3r_null = [r for r in results if r.get("nk3r_null")]
    kndy_null = [r for r in results if r.get("kndy_null")]
    print(f"Fezolinetant NDA 215902 — NK1R proxy misclassification: {len(nk1r_proxy)}/3")
    print(f"  NK3R/TACR3 receptor target absent: {len(nk3r_null)}/3")
    print(f"  KNDy neuron mechanism absent: {len(kndy_null)}/3")
    # Expected: all 3 platforms apply NK1R CINV aprepitant proxy; NK3R null in all three;
    # KNDy hypothalamic thermoregulatory mechanism absent; first NK3R drug ever = zero class precedent
asyncio.run(main())